QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • ABC News Features Advaxis, Inc. (ADXS) Cancer Immunotherapy 0 comments
    Nov 22, 2013 1:52 PM | about stocks: ADXS

    Cancer immunotherapies development leader Advaxis announced that ABC News recently featured ADXS-cHER2, the company's proprietary immunotherapy for treating breast cancer and canine osteosarcoma, in an article entitled "Bone Cancer Vaccine for Dogs Shows Promise for Breast Cancer."

    The company's Phase 1 canine osteosarcoma study evaluated the safety and efficacy of ADXS-cHER2 in companion dogs. The study was conducted by Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine. Results of the study show the dogs that received Advaxis immunotherapy are living significantly longer than the dogs whose owners chose not to participate in the study. Dogs with osteosarcoma have a median survival rate of only one year even with standard of care, which consists of amputation of the affected limb and follow-up chemotherapy. The first dog treated in the study, a 13-year-old American bulldog named Sasha, has survived over 600 days.

    ADXS-cHER2's proven ability to prolong the lives of companion dogs is an exciting development for both companion pet treatment and the drug product's potential for human candidates. Encouraging preliminary data exhibited in the dogs provides strong rationale for clinically developing ADXS-cHER2 as a treatment for women with HER2+ breast cancer.

    Advaxis believes this a potentially key value-creating opportunity to provide the company's immunotherapies for both the veterinary market and for women facing the growing global issue of breast cancer. The company is actively planning a clinical research program in the indication of HER2+ breast cancer in humans.

    For more information, visit advaxis.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.